Multiple Sclerosis

Last updated: 01 November 2019

You can legally access new medicines, even if they are not approved in your country.

Learn more »

Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).

Read more